BiotechTube

ALN-6400 + Placebo

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hereditary Hemorrhagic Telangiectasia

Conditions

Hereditary Hemorrhagic Telangiectasia

Trial Timeline

Nov 7, 2024 → Jun 22, 2028

NCT ID
NCT06659640

About ALN-6400 + Placebo

ALN-6400 + Placebo is a phase 1/2 stage product being developed by Alnylam Pharmaceuticals for Hereditary Hemorrhagic Telangiectasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06659640. Target conditions include Hereditary Hemorrhagic Telangiectasia.

What happened to similar drugs?

3 of 20 similar drugs in Hereditary Hemorrhagic Telangiectasia were approved

Approved (3) Terminated (0) Active (17)
✅Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injectionCSLApproved
✅GaradacimabCSLApproved
✅IdebenoneSanthera PharmaceuticalsApproved
🔄KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
🔄KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06659640Phase 1/2Recruiting

Competing Products

20 competing products in Hereditary Hemorrhagic Telangiectasia

See all competitors
ProductCompanyStageHype Score
KVD900KalVista PharmaceuticalsPhase 2
29
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 1
23
KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
SebetralstatKalVista PharmaceuticalsPre-clinical
20
KVD900 + Placebo to KVD900KalVista PharmaceuticalsPhase 1
23
SebetralstatKalVista PharmaceuticalsPre-clinical
24
Placebo + KVD900 600 mg + KVD900 300 mgKalVista PharmaceuticalsPhase 3
34
KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tabletKalVista PharmaceuticalsPhase 1
23
KVD900 150 mg + KVD900 300 mg + KVD900 600 mgKalVista PharmaceuticalsPhase 3
34
KVD824 + Placebo to KVD824KalVista PharmaceuticalsPhase 2
21
KVD900 600 mg + Drug: KVD900 300 mgKalVista PharmaceuticalsPhase 3
38
Deferasirox FCTNovartisPhase 2
27
Canakinumab + PlaceboNovartisPhase 3
40
IlarisNovartisPre-clinical
33
Standard of Care for Haemophilia ARochePre-clinical
26
EmicizumabRochePhase 3
40
TafamidisPfizerPre-clinical
26
tafamidisPfizerPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPre-clinical
26
NitisinoneSwedish Orphan BiovitrumPhase 1
29